Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration

BACKGROUND: Empagliflozin, an inhibitor of the sodium glucose co-transporter 2 (SGLT2) and developed as an anti-diabetic agent exerts additional beneficial effects on heart failure outcomes. However, the effect of empagliflozin on vascular cell function and vascular remodeling processes remains larg...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutzmann, Jochen, Bode, Lena Marie, Kalies, Katrin, Korte, Laura, Knöpp, Kai, Kloss, Frederik Julius, Sirisko, Mirja, Pilowski, Claudia, Koch, Susanne, Schenk, Heiko, Daniel, Jan-Marcus, Bauersachs, Johann, Sedding, Daniel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396257/
https://www.ncbi.nlm.nih.gov/pubmed/36017090
http://dx.doi.org/10.3389/fcvm.2022.956041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396257/
https://www.ncbi.nlm.nih.gov/pubmed/36017090
http://dx.doi.org/10.3389/fcvm.2022.956041

Ejemplares similares